The development of new cell replacement strategies using neural stem cells (NSC) may provide an alternative and unlimited cell source for clinical neural transplantation in neurodegenerative diseases such as Parkinson's and Huntington's disease. The clinical application of neural transplantation using NSC will therefore depend upon the availability of clinical grade NSC that are generated in unlimited quantities in a standardized manner. In order to investigate the utility of NSC in clinical neural transplantation, undifferentiated murine NSC were first expanded for an extended period of time in suspension bioreactors containing a serum-free medium. Following expansion in suspension bioreactors, NSC were still able to differentiate in vitro into both astrocytes and neurons after exposure to brain-derived neurotrophic factor (BDNF), suggesting that bioreactor expansion does not alter cell lineage potentiality. Undifferentiated bioreactor-expanded NSC were then transplanted into the rodent striatum. Immunohistochemical examination revealed undifferentiated bioreactor-expanded NSC survived transplantation for up to 8 weeks and expressed the astrocytic immunohistochemical marker glial fibrillary acidic protein (GFAP), suggesting that the host striatal environment influences NSC cell fate upon transplantation. Moreover, no tumor formation was observed within the graft site, indicating that NSC expanded in suspension bioreactors for an extended period of time are a safe source of tissue for transplantation. Future studies should focus on predifferentiating NSC towards specific neuronal phenotypes prior to transplantation in order to restore behavioral function in rodent models of neurodegenerative disease.
INTRODUCTION
optimizing transplant methodology (24) . These observations suggest that with further refinements, a cell restoration strategy may be a viable approach to brain repair The widespread use of fetal tissue as a cell replacement strategy to treat neurodegenerative diseases such in neurodegenerative diseases such as PD. If neural cell transplantation is to become a routine therapeutic option as Parkinson's disease (PD) is seriously limited by the critical lack of tissue availability, the potential for trans-for the treatment of neurological conditions in the future, there is a need to find an alternative and unlimited fer of microbiological or infectious agents, and ethical issues related to fetal cell procurement. Currently, over source of cells for clinical use.
Since the discovery of neural stem cells (NSC), con-350 patients have received fetal tissue transplants in numerous open-labeled trials as well as two double-blind, siderable attention has focused on the potential of these cells to provide a cell source for transplantation pur-randomized, placebo-controlled clinical trials of PD (9, 25) . Although one placebo-controlled clinical trial poses. NSC have the capacity to undergo stable in vitro self-renewal through multiple passages without loss of failed to meet its clinical endpoint, subject groups with less severe PD did show significant clinical improve-multipotency in the presence of mitogens such as epidermal growth factor (EGF) and fibroblast growth factor ment in both trials (9, 25) . Observations from an openlabel trial from our institution also indicate clinical effi-(FGF) (13, 15, 22, 28, 29, 36, 47) , and have the capacity to differentiate into enriched populations of glial and neu-cacy in patients following fetal tissue transplants when ronal progenitors following induction (21, 27) . Several
MATERIALS AND METHODS studies have demonstrated that NSC transplanted into
In Vitro Studies animal models of neurodegenerative disease can mi-Cell Lines. The cell line used in all experiments grate, proliferate, and integrate into the host brain (17, (W15) was a murine NSC line obtained from the labora-32). Furthermore, transplantation studies suggest that tory of Professor Sam Weiss at the University of Calthese cells can repopulate regions of lost cells and regary, Alberta. Primary cultures of murine cells were destore many of the functional deficits associated with cell rived as outlined by Reynolds and Weiss (28) . Briefly, loss in animal models of neural disease and injury (31, cells were obtained from the striatal region of the fore-40-42,49). In addition, NSC have been shown to differbrain of embryonic day 14 (E14) CD1 albino mouse ementiate into cells lineages that are appropriate for the bryos and immediately placed in NM medium (28) for environment into which they are grafted (2, 12, 20, 41, 44) . a period of 7 days. The cells (including spheroids) were Thus, NSC possess many of the characteristics to bethen harvested and placed in NM medium containing come an ideal source for cell replacement therapy in 10% DMSO, and stored in liquid nitrogen. neurodegenerative disorders.
Medium Preparation. The medium used to conduct The widespread application of clinical grade NSC in all experiments was PPRF-m4, a medium developed at transplantation procedures is highly dependent upon the the Pharmaceutical Production Research Facility. This development of methods to generate these cells in unculture medium was composed of the basal media limited quantities in a standardized fashion. Standard DMEM/F12 (1:1) (Invitrogen), 5 mM HEPES (Sigma), stationary culture vessels (such as tissue culture flasks) 0.6% glucose (Sigma), 1.73 g/L sodium bicarbonate are not amenable to scale-up for the production of large (Sigma), 2.0 mM glutamine (Invitrogen), 0.023 g/L innumbers of NSC (1) . Suspension culture bioreactors, sulin (Sigma), 20 nM progesterone (Sigma), 9.0 mg/L however, are an attractive alternative to stationary culputrescine (Sigma), 0.025 g/L transferrin (Sigma), 30 ture vessels because they are efficient, cost-effective, nM sodium selenite (Sigma), and 20 µg/L EGF (Peproand allow for quality-assured production of large quantitech). A proprietary supplement mixture was also added ties of stem cells under controlled conditions. Our group to the medium. The medium was vacuum filtered has previously developed suspension bioreactor protothrough a 0.22-µm bottle-top filter (Falcon) prior to use. cols using a specialized serum-free expansion medium (PPRF-m4) that enables the expansion of mammalian Cell Culture Equipment and Handling. After 3 months in cryostorage, the W15 primary cells were thawed and NSC populations as neurospheres under optimal oxygen, osmolarity, and pH conditions (1, 16, (37) (38) (39) . It has been placed in Nunc T-25 flasks containing 5 ml of PPRF-m4 for 2 days. The cells were then harvested, mechanically shown that the cells can be expanded for extended periods in PPRF-m4 without loss of defining characteristics dissociated by trituration, and inoculated at 75,000 cells/ ml into Nunc 75-cm 2 Easyflasks (Nunc) containing 15 as determined by karyotype analysis and immunohistochemistry (1, 16, 38, 39) . By setting up appropriate screen-ml of PPRF-m4 medium (passage level 1). After 4 days of incubation at 37°C, the NSC aggregates were har-ing protocols, it could be ensured that the generated cell populations are nontransformed, nontumorigenic, and vested, mechanically dissociated into a single-cell suspension, and reinoculated at 75,000 cells/ml into 125-free of microbiological agents. Moreover, if necessary, large numbers of cells could be manipulated (e.g., genet-ml suspension bioreactors (Corning Glass, Corning, NY) containing 100 ml of PPRF-m4 medium and placed on ically altered or induced to differentiate) prior to transplantation. Thus, the use of suspension bioreactors rep-Thermolyne Cell-Gro slow speed magnetic stirrers set at a speed of 100 rpm (Thermolyne, Dubuque, Iowa) (pas-resents an attractive approach for the production of unlimited quantities of clinical grade NSC for cell resto-sage level 2). The inner surface of the bioreactor and the outer surface of the magnetic stir bar were siliconized ration strategies.
A significant number of grafting studies have investi-with Sigmacote (Sigma, St. Louis, MO) prior to use to prevent the cells from adhering. All bioreactor runs were gated the behavioral recovery and cellular reinnervation of the host striatum following transplantation of NSC performed in duplicate. The cells were maintained in bioreactors until passage level 12 by serially subcultur-grown in static cultures. However, there have been no reports describing the transplantation of undifferentiated ing (mechanical dissociation) every 4 days for a total of 44 days. The passage level 12 spheroids were harvested, NSC grown for extended periods of time in suspension bioreactors. Therefore, the aim of this study was to in-placed in PPRF-m4 with 10% DMSO, and cryopreserved in liquid nitrogen. After 4 months in cryostorage, vestigate the ability of suspension bioreactors to rapidly expand NSC in serum-free media followed by examina-the cells were quickly thawed in a 37°C water bath for 5 min and placed into a 25-cm 2 Nunc T-flask for 2 days tion of host striatal environment influences on bioreactor-expanded NSC differentiation following neural in 5 ml of PPRF-m4 medium. After 2 days, the cells were harvested, triturated, and inoculated into fresh me-transplantation. dium (T-flasks) at 75,000 cells/ml. Cell density and via-rats were anesthetized using a mixture (2.0 ml/kg) of ketamine hydrochloride (Ketalean, MTC Pharmaceuti-bility were determined using a hemocytometer and the standard 0.1% trypan blue exclusion test (Sigma). The cals, Cambridge, Ontario), xylazine (Rompun, Miles Canada, Etobicoke, ON), and acepromazine maleate T-flasks were incubated at 37°C for 4 days (passage 13). This was repeated once (passage 14) in order to generate (Wyeth-Ayerst Canada, Montreal, QU) in 0.9% saline. Rats were then positioned in a Kopf stereotaxic instru-enough cells for transplantation. ment (Kopf Instruments, Tujunga, CA) and a midline Differentiation of Bioreactor-Expanded NSC. To descalp incision followed by a burr hole was performed. termine the potential of suspension bioreactor-expanded Cells were then transplanted using a glass capillary NSC to differentiate into neurons or glia prior to trans-(open diameter 50-70 µm) connected to a 2-µl Hamilton plantation, NSC were differentiated in 16-well chamber syringe at a rate of 1 µl/min. The capillary was left in slides. For differentiation, cell cultures containing bioreplace for 5 min before retrieval. Stereotactic coordinates actor-expanded neurospheres were collected and singlewere at the following coordinates from the dorsal surcell suspensions prepared by the incubation of neurosphface from bregma (mm): 1) AP = +1.3 mm, ML = −2.1 eres in 0.25% trypsin-EDTA (GIBCO) at 37°C for 5 min. 3 (substantia nireactor-expanded stem cells were then plated onto polygra) (26) . After transplantation, the muscle and skin L-lysine coated 16-well chamber slides (Falcon) and alwere closed with 000 polyglactin absorbable sutures lowed to differentiate for 7 days. All cultures were (Ethicon; Sommerville, NJ). All animals were immunomaintained at 37°C in a humidified culture incubator suppressed by daily injection of cyclosporin (10 mg/kg, with a 5% CO 2 atmosphere for 7 days, and finally ex-IP; Sandimmune, Sandoz Pharmaceuticals), beginning 1 posed to 4% paraformaldehyde (PFA) for 1 h prior to day prior to cell grafting and continuing until the concluimmunohistochemistry.
sion of the experiment 8 weeks later. Bioreactor-Expanded NSC Transplantation. Cell cultures containing bioreactor-expanded neurospheres were Tissue Preparation and Immunohistochemistry collected and single-cell suspensions prepared using At 8 weeks posttransplantation, animals were given 0.25% trypsin-EDTA (GIBCO) at 37°C for 5 min. Unan IP anesthetic overdose and perfused transcardially differentiated bioreactor-expanded NSC were gently tritwith 250 ml of cold 0.1 M phosphate-buffered saline urated into a single-cell suspension after the addition of (PBS), pH 7.4, followed by 250 ml of 4% PFA in 0.1 M 0.05% DNase/DMEM, centrifuged at 1,500 rpm for 5 PBS for 15 min. The brain was removed and postfixed min, and finally resuspended in 1 ml of 0.05% DNase/ overnight in 4% PFA in 0.1 M PBS at 4°C followed by DMEM. Cell density and viability measurements were cryoprotection overnight in 30% sucrose in 0.1 M PBS then determined using a hemocytometer prior to transat 4°C. Brains were then cut in 40-µm coronal sections plantation. Cell viabilities were ≥98% as determined by on a Leitz freezing microtome at −37°C and stored in the trypan blue dye exclusion method.
Millonig's solution (16.88 mg/ml NaH 2 PO 4 H 2 O, 3.86 mg/ml NaOH, 0.006% NaAzide in distilled water).
In Vivo Studies
Immunofluorescence and confocal microscopy was also performed. Briefly, 40-µm sections and chamber A total of eight adult female albino Wistar rats (Charles River, St. Constant, Quebec) (200-225 g) were slides were rinsed twice for 5 min in 0.1 M phosphate buffer (PB), preincubated in a diluent of 8% normal goat housed with water and food ad libitum in a colony room maintained on a 12:12 h light/dark cycle at constant serum (NGS) in 0.3% Triton X-100 in 0.1 M PB at room temperature for 1 h. Sections and chamber slides were temperature (19-22°C) and humidity (40-50%). All transplantation procedures were performed at the Neuro-then placed in diluents employing mouse anti-neuronal nuclei (NeuN) (1:1000, Chemicon), mouse anti-O4 (O4) transplantation Laboratory, Dalhousie University, in accordance to the Guidelines of the Canadian Council of (1:1000, Chemicon), mouse anti-glial fibrillary acidic protein (GFAP) (1:1000, NovaCastra), mouse anti-TUJ-Animal Care and the Dalhousie University Animal Care Committee.
1 (1:1000, Chemicon), mouse anti-Ki-67 (1:500, Chemicon), or rat anti-M2 (1:500, Iowa Hybridoma Bank) an-A single-cell suspension of 50,000 undifferentiated bioreactor-expanded NSC was injected stereotactically tibodies overnight at room temperature. The sections and chamber slides were rinsed again and placed in dilu-into the striatum as previously described (23) . Briefly, Embryonic day 14 (E14) CD1 albino mouse striatal NSC were cultured for a total of 13 days in stationary culture (T-flasks) prior to being inoculated into suspension culture bioreactors. Aggregates in stationary culture were mechanically dissociated into single cells and inoculated at 75,000 cells/ml into 125-ml spinner flask bioreactors containing 100 ml of PPRF-m4 medium agitated at 100 rpm. The bioreactors were incubated at 37°C in a humidified atmosphere containing 5% CO 2 in air. The cells were subcultured in new bioreactors containing fresh medium after every 4th day for a total of 11 passages (44 days). ent containing the secondary Ab (goat anti-rabbit 1:200, average cell density over the same time period was approximately 7.0 × 10 5 cells/ml. This represents 3.2 dou-Cy2; goat anti-mouse 1:200, Cy2; goat anti-rat, 1:500, Cy3) for 1 h at room temperature. The sections were blings over 4 days, or an average cell population doubling time of 30 h. then mounted on gelatin-coated slides, and sections and chamber slides were coverslipped with Vectorshield Differentiation of Bioreactor-Expanded NSC. Immumountant media. The sections and chamber slides were nohistochemical analysis of the differentiated bioreacviewed using confocal microscopy.
tor-expanded NSC revealed extensive staining for the intermediate filament stem cell marker nestin ( Fig. 2A) ,
RESULTS
the astrocytic marker GFAP (Fig. 2B) , and the neuronal In Vitro Studies filament marker TUJ-1 (Fig. 2C) . Each of these colabeled with the mouse specific marker M2 (Fig. 2D ).
Expansion of Cells in Suspension Culture Bioreac-
These findings reveal that bioreactor-expanded NSC tors. Following culturing in the suspension bioreactor, have the potential to differentiate into both astrocytic NSC formed aggregates that were relatively uniform in and neuronal lineages after extended passaging in a sussize as a result of the controlled hydrodynamic shear pension bioreactor culture system. within the bioreactor environment. A minimal amount of cell debris was also present. During each subculture,
In Vivo Studies a representative sample was isolated and used to determine cell density and viability (Fig. 1) . The average via-Immunohistochemical and confocal analysis of the striatum indicated viable bioreactor-expanded NSC bility over 11 passages was approximately 73% and the grafts (Fig. 3) . Bioreactor-expanded NSC were observed and an unlimited source of cells such as NSC for clinical use. Standard stationary cultures are not amenable to to undergo differentiation into GFAP-positive astrocytes within the striatum that colabeled with the murine-scale-up for the production of large numbers of NSC for potential clinical use (29, 46) . Suspension bioreactors specific astroglial marker M2. Staining with the neuronal filament marker TUJ-1 or the oligodendrocyte generate a stable and homogenous environment for the reproducible expansion of NSC by maintaining optimal marker O4 revealed bioreactor-expanded NSC did not differentiate into neurons or oligodendrocytes (data not oxygen levels, ensuring desirable physicochemical conditions, and controlling hydrodynamic effects. Further-shown). There was no evidence of tumor formation following bioreactor-expanded NSC transplantation into more, bioreactors are amenable to continuous perfusion of fresh medium and removal of waste products, and the striatum up to 8 weeks after surgery as determined by the lack of expression of the cell cycle-associated therefore promote cell expansion by maintaining optimum growth conditions (1, (14) (15) (16) (36) (37) (38) (39) . protein Ki-67, which labels the nuclei of proliferating cells during late G 1 , S, G 2 , and M phase of the cell cycle
In the present study, NSC isolated from the striatal regions of the forebrain of E14 CD1 albino mouse em- (Fig. 4) .
bryos and serially passaged 11 times in a 125-ml suspen-DISCUSSION sion bioreactor exhibited an average doubling time of 30 h and an average viability of 73%. The cell viability If neural transplantation is to become a routine therapeutic option for the treatment of neurodegenerative dis-reported in the current study is typical of mammalian cells that are derived from neurospheres undergoing eases, there is a need to find an alternative to fetal tissue mechanical dissociation (14- 16, 37, 38) . Although little current study, NSC were expanded as aggregates in the presence of EGF and bFGF. In vitro analysis revealed variability in both average diameter and cell packing density of neurospheres was observed, culture hydrody-undifferentiated bioreactor-expanded NSC are multipotent. Specifically, undifferentiated bioreactor-expanded namics can be manipulated to control these variables (37) . In addition, we have also characterized the impact NSC can differentiate into astrocytic and neuronal lineages, as observed by staining for the intermediate fila-of medium viscosity and power input on cell proliferation and neurosphere size (38) . In the bioreactors, the ment stem cell marker nestin, the astrocytic marker GFAP, and the immature neuronal filament marker TUJ-inoculated single cells rapidly formed aggregates, and it was demonstrated through immunohistochemistry that 1 that colabeled with the mouse-specific marker M2. These findings suggest that bioreactor expansion of NSC the stem cells within these aggregates did not lose their defining characteristics (15, 37, 38) . The murine NSC do not alter the nature of the NSC or their differentiation capabilities. were not transformed and had a modal metaphasic chromosome number of 40 (diploid number = 20). A significant number of transplantation studies have been completed using NSC grown in static cultures. Our group has previously shown that it is possible to obtain large expansion ratios (10 7 in 35 days) of murine However, the study presented here is the first to describe the transplantation of NSC expanded in suspension bio-NSC in suspension bioreactors without the loss of pluripotency (14). Previous studies have also shown that reactors. Confocal microscopy revealed transplanted bioreactor-expanded NSC retained the potential to survive NSC have the capacity to undergo stable in vitro asymmetric division through multiple passages without loss and differentiate into mature GFAP-expressing astrocytes that colabeled with the mouse-specific marker M2 of multipotency in the presence of mitogens such as EGF, FGF, and transforming growth factor-α (TGF-α) within the striatum after 8 weeks. However, undifferentiated bioreactor-expanded NSC did not differentiate (13, 15, 22, 28, 29, 36, 47) . Under these conditions, cultured NSC can be induced to differentiate into enriched popu-into neurons or oligodendrocytes as observed by the lack of NeuN, TUJ-1, or O4 colabeling upon transplantation. lations of glial and neuronal progenitors (21, 27) . In the This lack of differentiation in vivo may be due to envi-adult CNS, such as the striatum and spinal cord (3, 6, 10, 45) . In contrast, studies transplanting into neurogenic ronmental factors influencing differentiation in the host brain. Furthermore, transplanted bioreactor-expanded regions of the brain such as the hippocampus have shown that NSC have the capacity to differentiate into neurons NSC did not undergo tumor formation as determined by the lack of expression of the cell cycle-associated pro-(7,8,10,11). The mechanism that regulates lineage restriction remains to be determined; however, it has been tein Ki-67, which labels the nuclei of proliferating cells during late G 1 , S, G 2 , and M phase of the cell cycle.
suggested that glial restrictive cues may predominate over neuronal NSC differentiation (4) . Thus, the trans-Considering that bioreactor-expanded NSC were lineage restricted to a glial fate following transplantation, plantation of bioreactor-expanded NSC committed to a specific neuronal lineage via predifferentiation prior to the host environment was not conducive to directing these cells to a neuronal phenotypic fate. These current transplant may be more beneficial over undifferentiated NSC in rodent models of neurodegenerative disease. findings are supported by studies of adult NSC that have previously been shown to differentiate into primary glia Studies utilizing the transplantation of undifferentiated human embryonic NSC into the striatum in a 6-when transplanted into nonneurogenic regions of the in vivo (5, 35, 50) , have also shown that NSC can be in-9. Freed, C. R.; Greene, P. E.; Breeze, R. E.; Tsai, W. Y.; duced to differentiate into tyrosine hydroxylase-express-
